William Blair Dumps $21 Million of Healthcare Platform Doximity Stock
Key Points
William Blair sold 372,184 shares of Doximity; estimated trade size was $20.89 million (quarterly average pricing).
Quarter-end Doximity position value fell by $184.77 million, reflecting both trading and price changes.
The transaction represented 0.06% of 13F reportable assets under management.
Post-sale, the fund held 5,456,985 shares valued at $241.64 million.
Doximity was 0.67% of AUM after the trade, placing it outside the fund’s top five holdings.
- 10 stocks we like better than Doximity ›
What happened
According to a Securities and Exchange Commission (SEC) filing dated Feb. 9, 2026, William Blair Investment Management, LLC reduced its position in Doximity (NYSE:DOCS) by 372,184 shares during the fourth quarter of 2025. The estimated transaction value was $20.89 million, calculated using the average closing price over the quarter. The quarter-end value of the Doximity stake decreased by $184.77 million, reflecting both share sales and stock price movements.
What else to know
This sale was a partial reduction; Doximity represented 0.67% of the fund’s reportable assets under management at quarter-end.
- Top holdings after the filing:
- Nvidia: $1.98 billion (5.5% of AUM)
- Taiwan Semiconductor Manufacturing: $1.82 billion (5.1% of AUM)
- Microsoft: $1.69 billion (4.7% of AUM)
- Apple: $1.48 billion (4.1% of AUM)
- Amazon: $1.01 billion (2.8% of AUM)
As of Feb. 6, 2026, Doximity shares were priced at $27.73, down 66% from a year earlier, underperforming the S&P 500 by 82 percentage points over that period.
Company Overview
| Metric | Value |
|---|---|
| Price (as of market close 2/6/26) | $27.73 |
| Market Capitalization | $5.09 billion |
| Revenue (TTM) | $637.78 million |
| Net Income (TTM) | $239.40 million |
Company Snapshot
Doximity:
- Operates a cloud-based digital platform offering collaboration, telehealth, and career management tools for medical professionals in the United States.
- Generates revenue primarily from pharmaceutical manufacturers and healthcare systems.
- Targets physicians, healthcare providers, and medical organizations as its primary customer base.
Doximity connects U.S. medical professionals through a cloud-based digital platform serving healthcare and pharmaceutical clients. Doximity is a leading healthcare information services provider that leverages a robust digital platform to connect and empower medical professionals.
What this transaction means for investors
While William Blair’s $21 million sale of Doximity may seem like a big deal, it only accounted for roughly 15% of the firm’s shares of the stock. What might be more interesting to watch regarding William Blair and Doximity is what the firm will do with the stock this quarter. Reporting Q3 earnings earlier in February, Doximity’s stock plummeted to just $27 per share -- about 67% below its 52-week high. With Doximity now trading at just 17 times free cash flow -- its lowest-ever valuation -- I’ll be curious to see if William Blair doubles down on its holding or keeps selling.
Regarding the promising healthcare platform itself, I think there is still a lot to like about Doximity, and that its continued sell-off throughout the year is well overdone. Yes, sales growth slowed from 23% in Q3 last year to 10% this year -- and management guided for only 4% growth in Q4 -- but I believe this reflects a confluence of short-term factors rather than any long-term issues.
Pharmaceutical companies love to advertise on Doximity’s platforms because 85% of U.S. physicians and two-thirds of physicians’ assistants and nurse practitioners use the platform. However, 16 of the top 20 U.S. pharma companies delayed major spending decisions (such as advertising with Doxmity) as they ironed out most-favored-nation agreements. With this headwind now subsiding, Doximity board member Tim Cabral noted that the company’s pharma bookings growth rates in January were the best in its history, pointing toward eventual recovery. Best yet for investors, Doximity will look to fully launch and monetize its array of AI applications in 2026, so I could only look to keep adding to one of my favorite stocks while it trades at such a reasonable price -- maybe William Blair will, too.
Should you buy stock in Doximity right now?
Before you buy stock in Doximity, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Doximity wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $443,299!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,136,601!*
Now, it’s worth noting Stock Advisor’s total average return is 914% — a market-crushing outperformance compared to 195% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of February 9, 2026.
Josh Kohn-Lindquist has positions in Doximity and Nvidia. The Motley Fool has positions in and recommends Amazon, Apple, Doximity, Microsoft, Nvidia, and Taiwan Semiconductor Manufacturing. The Motley Fool has a disclosure policy.
Recommended Articles
